HUP0500525A2 - Transzdermális terápiás rendszer parkinsonkórhoz rotigotin magas plazmaszintjeit indukálva - Google Patents

Transzdermális terápiás rendszer parkinsonkórhoz rotigotin magas plazmaszintjeit indukálva

Info

Publication number
HUP0500525A2
HUP0500525A2 HU0500525A HUP0500525A HUP0500525A2 HU P0500525 A2 HUP0500525 A2 HU P0500525A2 HU 0500525 A HU0500525 A HU 0500525A HU P0500525 A HUP0500525 A HU P0500525A HU P0500525 A2 HUP0500525 A2 HU P0500525A2
Authority
HU
Hungary
Prior art keywords
rotigotine
parkinson
therapeutic system
transdermal therapeutic
plasma levels
Prior art date
Application number
HU0500525A
Other languages
English (en)
Inventor
Thomas Lauterbach
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Walter Müller
Original Assignee
Schwarz Pharma Ag
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0500525(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag, Lts Lohmann Therapie-Systeme Ag filed Critical Schwarz Pharma Ag
Publication of HUP0500525A2 publication Critical patent/HUP0500525A2/hu
Publication of HU229350B1 publication Critical patent/HU229350B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Optical Elements Other Than Lenses (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

A találmány szilikonalapú transzdermális terápiás rendszeralkalmazását biztosítja, ahol a transzdermális rendszer területe 10cm2 és 40cm2 között van, és aktív alkotórészként 0,1 mg/cm2 és 3,15mg/cm2 között tartalmaz rotigotint. Az alkalmazás Parkinson-kór-ellenes gyógyszerek készítésére vonatkozik, amely gyógyszer 0,4 ng/mlés 2 ng/ml közti tartományban indukálja a rotigotin átlagosplazmakoncentrációját 24 órával a beadás után.
HU0500525A 2001-05-08 2002-05-06 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine HU229350B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111109A EP1256339B1 (en) 2001-05-08 2001-05-08 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
PCT/EP2002/004976 WO2002089778A2 (en) 2001-05-08 2002-05-06 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine

Publications (2)

Publication Number Publication Date
HUP0500525A2 true HUP0500525A2 (hu) 2005-09-28
HU229350B1 HU229350B1 (en) 2013-11-28

Family

ID=8177356

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500525A HU229350B1 (en) 2001-05-08 2002-05-06 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine

Country Status (15)

Country Link
EP (3) EP1344522A1 (hu)
JP (2) JP5026656B2 (hu)
KR (1) KR100974974B1 (hu)
CN (2) CN102172351B (hu)
AT (2) ATE251901T1 (hu)
CY (1) CY1109861T1 (hu)
DE (2) DE60100994T2 (hu)
DK (2) DK1256339T3 (hu)
ES (2) ES2204780T3 (hu)
HK (1) HK1049444B (hu)
HU (1) HU229350B1 (hu)
PT (2) PT1256339E (hu)
RU (1) RU2272625C2 (hu)
WO (1) WO2002089778A2 (hu)
ZA (1) ZA200209982B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011048491A2 (en) * 2009-10-19 2011-04-28 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
EP3257504B1 (en) 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
DE102014114282A1 (de) 2014-10-01 2016-04-07 Neuraxpharm Arzneimittel Gmbh Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson
CN110121344A (zh) 2016-12-28 2019-08-13 久光制药株式会社 含布托啡诺的贴附剂
DE102018120505A1 (de) 2017-10-20 2019-04-25 Amw Gmbh Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751515B2 (ja) * 1986-09-10 1995-06-05 明治製菓株式会社 経皮吸収製剤
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Also Published As

Publication number Publication date
DK1471892T3 (da) 2009-12-07
JP2010106037A (ja) 2010-05-13
CN1606435A (zh) 2005-04-13
EP1344522A1 (en) 2003-09-17
KR20030016373A (ko) 2003-02-26
PT1256339E (pt) 2004-02-27
HK1049444A1 (en) 2003-05-16
CN102172351A (zh) 2011-09-07
RU2003133217A (ru) 2005-04-20
EP1256339B1 (en) 2003-10-15
EP1256339A1 (en) 2002-11-13
ES2331787T3 (es) 2010-01-15
ATE251901T1 (de) 2003-11-15
PT1471892E (pt) 2009-12-23
DK1256339T3 (da) 2004-02-09
JP5026656B2 (ja) 2012-09-12
ES2204780T3 (es) 2004-05-01
HU229350B1 (en) 2013-11-28
DE60100994T2 (de) 2004-07-22
EP1471892A2 (en) 2004-11-03
WO2002089778A2 (en) 2002-11-14
ZA200209982B (en) 2003-03-24
CN102172351B (zh) 2013-07-17
RU2272625C2 (ru) 2006-03-27
JP2004536054A (ja) 2004-12-02
HK1049444B (zh) 2004-03-19
KR100974974B1 (ko) 2010-08-09
CY1109861T1 (el) 2014-09-10
WO2002089778A3 (en) 2004-08-19
EP1471892B1 (en) 2009-09-30
DE60100994D1 (de) 2003-11-20
ATE444061T1 (de) 2009-10-15
DE60233898D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
HUP0500525A2 (hu) Transzdermális terápiás rendszer parkinsonkórhoz rotigotin magas plazmaszintjeit indukálva
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
HUP0401568A2 (hu) Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
BRPI0410542A (pt) dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
CA2601289A1 (en) Once-a-day oxycodone formulations
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
KR20090024277A (ko) 여러 가지 타입의 통증의 예방, 경감 및/또는 치료를 위한 약제의 제조에 있어 치환 2-아미노테트랄린의 사용
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
HUP0402213A2 (hu) Propilénglikolmonokaprilátot tartalmazó szteroid hormontartalmú transzdermális terápiás rendszer
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
BR0107881A (pt) Uso de fsh tratamento de infertilidade
HUP0402062A2 (hu) Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények
JP2008514376A5 (hu)
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
HUP0300970A2 (hu) Epinastint és pszeudoefedrint tartalmazó új gyógyszerkészítmények
TH53654B (th) การรักษาสภาพภูมิแพ้และสภาพอักเสบ
TH53654A (th) การรักษาสภาพภูมิแพ้และสภาพอักเสบ

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: UCB PHARMA GMBH, DE

Free format text: FORMER OWNER(S): SCHWARZ PHARMA AG, DE

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, DE

Free format text: FORMER OWNER(S): SCHWARZ PHARMA AG, DE